Division of Clinical Neurology
Who is based in this Division?
t: 01865 234829 e: email@example.com
What do we do?
Diseases of the central nervous system include many of the most disabling conditions, such as multiple sclerosis (MS), stroke, motor neuron disease (MND), Alzheimer’s disease and Parkinson’s disease. These disorders have great cost to patients, their family and carers, and to society as a whole.
We want to understand underlying disease mechanisms in order to treat these conditions effectively.
We are based in the West Wing of the John Radcliffe Hospital. This provides the perfect setting to share facilities, expertise and knowledge, as well as realise our goal of applying our learning in clinical practice.
28 May 2021
Professor David Bennett is leading a new national research consortium to investigate neuropathic pain.
16 February 2021
Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.
Academic Neuropathology Unit
We want to understand how - and why - brain function can be disturbed to lead to poor memory and loss of motivation (apathy). Our aim is to develop new treatments for these conditions across a range of neurological disorders.
Neuromyelitis optica (NMO) is a rare disease causing inflammation in the spinal cord and optic nerves. The NMO service brings together expertise in diagnostics and clinical management to improve outcomes for this often isolated group of patients.
Glycosylation is one of the most common and poorly understood forms of post-translational modification. Our aim is to understand the biochemical mechanisms underlying protein glycosylation, as well as decipher the roles that they play in health and disease.
Our research aims to understand the characteristics of individual brain tumours, combining cutting edge brain imaging, molecular neuropathology and neurosurgical techniques to develop personalized approaches for first-line cancer surgery.
Our group uses computer simulations and mathematical analyses to understand the information processing and activity dynamics of brain networks underlying decision making. We use these models to investigate how neural circuits work in the healthy state, how their dynamics deteriorate in neurological disorders, and how their dynamics and information processing may be best restored by treatments.
Our aim is to understand fundamental biological processes that could inform the development of targeted therapies and innovative biomarkers in neurodegenerative and neurogenetic disorders.
Our group aims to deliver the highest quality translational and clinical research within both investigator- and commercial-led clinical trials with a focus on relieving the disease burden of MS to patients and their carers.
Our aim is to gain a better understanding of the response of the peripheral nervous system to injury in order to develop strategies to promote peripheral nerve repair and to prevent the development of neuropathic pain. To do this we employ a variety of multi-disciplinary techniques ranging from transgenic models to human psychophysical studies and genetics.
This cross-disciplinary research group links neuropathology, endocrinology and molecular genetics to explore how the genetics and epigenetics of pituitary tumours influences clinical characteristics and to identify targets for therapeutic intervention.
We explore the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases using a multidisciplinary team approach to post-mortem brain and spinal cord tissue. The aim is that the understanding derived from these studies will translate into ideas for improved treatments for living patients.
We work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.
We are a forward-looking dynamic group interested in all aspects of clinical and experimental epileptology with an emphasis on clinically relevant research. The Group draws together all relevant disciplines across Oxford University Hospitals and the University of Oxford.
We study why certain neuronal populations are vulnerable to neurodegeneration in Parkinson’s disease brain and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.